Last reviewed · How we verify
NCT01547143: HELA2012
Pilot Study of First-line Immunosuppressive Therapy Combined With Etoposide and Allogeneic Hematopoietic Cell Transplantation in Refractory/Reactivated Cases for Hemophagocytic Lymphohistiocytosis (HLH) in Adult Patients
NA trial testing IST and/or alloHCT in Hemophagocytic Lymphohistiocytosis in 12 participants. Terminated before completion.
1 May 2016
Quick facts
| Lead sponsor | Asan Medical Center |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 1 March 2012 |
| Primary completion | 1 May 2016 |
| Estimated completion | 1 May 2016 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- IST and/or alloHCT — full drug profile →
Conditions studied
- Hemophagocytic Lymphohistiocytosis — all drugs for Hemophagocytic Lymphohistiocytosis →
Sponsor
Asan Medical Center
Who can join
Adults 18 to 80, any sex, with Hemophagocytic Lymphohistiocytosis. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
overall survival rate
Time frame: 1-year
Sponsor's own description
The investigators would like to propose a pilot study evaluating the efficacy of etoposide combined with immunosuppressive agents for adult secondary hemophagocytic lymphohistiocytosis (HLH), in order to prove out whether the modification of previous HLH-94 or HLH-2004 protocol for childhood patients can improve the outcome and decrease the toxicities. The results of this pilot study will be a base of a more-improved phase-2 protocol.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Hemophagocytic Syndrome and Critical Illness: New Insights into Diagnosis and Management.
Tothova Z, Berliner N. · · 2015 · cited 70× · PMID 24407034 · DOI 10.1177/0885066613517076
Verify or expand the search:
- PubMed search for NCT01547143
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Asan Medical Center trials
Trials by the same sponsor.
- NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
- NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
- NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
- NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
- NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01547143 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
- Last refreshed: 19 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01547143.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing